Provectus Biopharmaceuticals Management

Management criteria checks 4/4

Provectus Biopharmaceuticals' CEO is Ed Pershing, appointed in Apr 2024, has a tenure of less than a year. directly owns 0.75% of the company’s shares, worth $359.34K. The average tenure of the management team and the board of directors is 3.1 years and 5.3 years respectively.

Key information

Ed Pershing

Chief executive officer

US$75.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.8%
Management average tenure	3.1yrs
Board average tenure	5.3yrs

Recent management updates

Recent updates

CEO

Ed Pershing (71 yo)

less than a year

Tenure

US$75,000

Compensation

Mr. Edward V. Pershing, also known as Ed, CPA has been Chairman of Provectus Biopharmaceuticals, Inc., since April 27, 2018 and serves as its Chief Executive Officer since April 2024. He served as the Chie...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Edward Pershing	CEO & Chairman of Board	less than a year	US$75.00k	0.75% $ 359.3k
Dominic Rodrigues	President & Vice Chairman of the Board	7.6yrs	US$75.00k	0.26% $ 122.5k
Eric Wachter	Co-Founder & CTO	12.5yrs	US$253.25k	1.58% $ 756.0k
Heather Raines	Chief Financial Officer	5.7yrs	US$125.00k	0.29% $ 137.9k

3.1yrs

Average Tenure

59yo

Average Age

Experienced Management: PVCT's management team is considered experienced (3.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Edward Pershing	CEO & Chairman of Board	6.6yrs	US$75.00k	0.75% $ 359.3k
Dominic Rodrigues	President & Vice Chairman of the Board	7.6yrs	US$75.00k	0.26% $ 122.5k
Frank Akers	Member of Strategic Advisory Board	5.3yrs	no data	no data
John Lacey	Chairman of Strategic Advisory Board & Independent Director	6.6yrs	US$80.00k	0.048% $ 22.7k
Harold Schmitz	Member of Scientific Advisory Board	5.2yrs	no data	no data
Webster Bailey	Independent Director	4.8yrs	US$80.00k	no data
Aru Narendran	Member of Scientific Advisory Board	2.6yrs	no data	no data

5.3yrs

Average Tenure

63yo

Average Age

Experienced Board: PVCT's board of directors are considered experienced (5.3 years average tenure).

Provectus Biopharmaceuticals Management

Management criteria checks 4/4

Key information

Recent management updates

Provectus Biopharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer

Provectus Biopharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board

Recent updates

Provectus Biopharmaceuticals, Inc. announced a financing transaction

Provectus Biopharmaceuticals, Inc. Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting

Provectus Biopharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer

Provectus Biopharmaceuticals, Inc. Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting

Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Advanced Cutaneous Melanoma

Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Metastatic Uveal Melanoma

Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10(R) and Keytruda(R) for First-Line Stage III Melanoma at Melanoma Bridge 2022

Provectus Biopharmaceuticals Presents Data from PV-10 Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology (ISOO) Congress

Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunotherapy in Hematology

Provectus Biopharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract for Oral Presentation at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference

Provectus Biopharmaceuticals Provides Update on Research into PV-10 Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better

Provectus Biopharmaceuticals, Inc. Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research 2021 Congress

Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10 at European Society for Medical Oncology (ESMO) Congress 2021

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract At European Society for Medical Oncology (ESMO) Congress 2021

Provectus Biopharmaceuticals Announces Publication of In Vitro Data from Research on Oral Delivery of PV-10® at American Society of Clinical Oncology 2021 Annual Meeting

Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Provectus Biopharmaceuticals, Inc. Directs Funding in the Amount of $2.5 Million to Develop Animal Health Drug Products Through Partnerships with State Universities That Have Agriculture and Veterinary Medicine Programs and the Knoxville-Headquartered Biotechnology Company

Provectus Biopharmaceuticals Announces Acceptance of PV-10 Immunotherapy Abstracts at American Society of Clinical Oncology 2021 Annual Meeting

Provectus Biopharmaceuticals Announces Release of Preprint Manuscript Describing Preclinical Study of Pv-10® Immunotherapy and Chemotherapy for Treatment of Pancreatic Cancer

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Melanoma Abstract for Oral Presentation at Melanoma Bridge 2020

Provectus Biopharmaceuticals, Inc. Announces Acceptance of PV-10® Pancreatic Cancer Abstract at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Provectus Biopharmaceuticals Completes Enrollment of PV-10® Study for Treatment of Symptomatic Neuroendocrine Tumors Metastatic to the Liver Refractory to Somatostatin Analogs and Peptide Receptor Radionuclide Therapy

Provectus Biopharmaceuticals, Inc. Highlights Stage Iv M1c Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma At ESMO Virtual Congress 2020

Provectus Biopharmaceuticals, Inc. Announces Presentation of 2-Year Data from Combination Therapy Trial of PV-10 and KEYTRUDA for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age